Celebrity Announcements of Breast Cancer Underscore Increasing Prevalence in Younger Women

Many young celebrities have recently announced that they have been diagnosed with breast cancer. This is a clear pointer to the public that cases of this disease among younger women not yet 50 years of age are rising in America.

For example, Jessie J, a pop singer aged 37, took to Instagram last week to reveal her intention to under surgery in a few weeks after her early-stage diagnosis of breast cancer. Katie Thurston, who starred in “The Bachelorette,” has been active on social media sharing about her journey after being diagnosed with stage-four breast cancer. She is 34 years old. Danielle Fishel, an actor, went public about her breast cancer diagnosis last summer. Fishel is 43 years old. The list goes on and on.

There has been a marked rise in diagnoses of breast cancer among younger women in the last 10 years. Available data indicates cases have risen by 1.4% each year between 2012 and 2021 in women less than 50 years of age while those above 50 have seen a 0.7% uptick each year within that duration.

This trend is affecting women from all ethnic or racial groups, but especially for Pacific Island and Asian American women whose case prevalence has spiked by almost 50% from 2000. For Black women, the prevalence of the disease among those under 40 years is highest and the likelihood of death for those diagnosed is highest among this group.

It has been a normal practice to recommend breast mammograms to women once they hit 50 and those below 40 rarely get advised to undergo this screening procedure unless specific factors make them predisposed to breast cancer. These include having a genetic predisposition or a history of the disease.

Several doctors specializing in treating breast cancer are now saying that younger women and their healthcare providers should now regard symptoms like nipple discharges and lumps more seriously since they could point to an early onset of this disease.

This warning is especially important because younger women have a higher likelihood of developing aggressive forms of breast cancer, such as the triple-negative form. Catching the disease early therefore increases the odds of favorable clinical outcomes. It isn’t yet clearly understood why ladies under 35 years diagnosed with breast cancer also tend to have the disease metastasize to other parts of the body, which isn’t common among older women.

Clinicians say the increasing incidence of breast cancer among younger women could be due to a combination of several factors, such as environmental, lifestyle and genetic factors. These rising cases make it more urgent to develop effective treatments against this disease. Entities like Calidi Biotherapeutics Inc. (NYSE American: CLDI) have taken on this challenge, particularly against triple-negative breast cancer.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN